Although its expression levels are unaffected in CLL cells, SHP-1 activity is inhibited as a result of phosphorylation of the inhibitory residue Ser591 (26), making it an interesting molecular target for the treatment of this disease. The gene discussed is PTPN6; the disease is B-cell chronic lymphocytic leukemia.